About Genelux
Genelux (NASDAQ:GNLX) is a biopharmaceutical company dedicated to pioneering innovative treatments for cancer patients. It centers its efforts on developing oncolytic viral therapies, a cutting-edge approach that leverages viruses to selectively kill cancer cells while sparing healthy tissues. Genelux's project portfolio highlights its flagship candidate, Olvi-Vec, designed for the treatment of solid tumor cancers through direct injection into tumors, showcasing promising clinical trial outcomes. With a steadfast commitment to transforming cancer treatment, Genelux's objectives include advancing its clinical programs, expanding its therapeutic pipeline, and ultimately improving patient outcomes by delivering safer and more effective cancer therapies.
Snapshot
Operations
Products and/or services of Genelux
- Oncolytic vaccinia virus technologies for cancer therapies, leveraging virus's ability to selectively infect and kill cancer cells.
- Development of Olvimulogene Nanivacirepvec (GL-ONC1), an intravenously delivered treatment for peritoneal carcinomatosis.
- Research into viral vector platforms for delivering therapeutic genes directly into cancer cells.
- Advancements in imaging and diagnostic tools using modified viruses to target and illuminate cancerous tissues.
- Design of combination therapies integrating virus-based treatments with current cancer care practices, such as chemotherapy and radiation.
- Collaborations with academic and industry partners to explore new indications for viral therapy in oncology.
Genelux executive team
- Mr. Thomas D. Zindrick J.D.Chairman, CEO & President
- Dr. Joseph Cappello Ph.D.Chief Technical Officer
- Mr. Matthew Pulisic M.B.A.CFO and Principal Financial & Accounting Officer
- Mr. Eric Groen J.D.General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development
- Dr. Yong Yu Ph.D.Senior Vice President of Clinical Development
- Mr. Ralph Smalling B.Sc.VP & Head of Regulatory Affairs
- Dr. Jason B. Litten M.D.Chief Medical Officer